title: Cell growth regulation through GM3-enriched microdomain (glycosynapse) in human lung embryonal fibroblast WI38 and its oncogenic transformant VA13.
abstract: Cell growth control mechanisms were studied based on organization of components in glycosphingolipid-enriched microdomain (GEM) in WI38 cells versus their oncogenic transformant VA13 cells. Levels of fibroblast growth factor receptor (FGFR) and cSrc were 4 times and 2-3 times higher, respectively, in VA13 than in WI38 GEM, whereas the level of tetraspanin CD9/CD81 was 3-5 times higher in WI38 than in VA13 GEM. Csk, the physiological inhibitor of cSrc, was present in WI38 but not in VA13 GEM. Functional association of GEM components in control of cell growth in WI38 is indicated by several lines of evidence. (i) Confluent, growth-inhibited WI38 showed a lower degree of FGF-induced MAPK activation than actively growing cells in sparse culture. (ii) The level of inactive cSrc (with Tyr-527 phosphate) was higher in confluent cells than in actively growing cells. Both processes i and ii were inhibited by GM3 since they were enhanced by GM3 depletion with d-threo-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4). (iii) The high level of inactive cSrc associated with growth-inhibited cells was caused by coexisting Csk in WI38 GEM. (iv) Interaction of GM3 with FGFR was demonstrated by binding of GM3 to FGFR in the GEM fraction, as probed with GM3-coated beads, and by confocal microscopy. In contrast to WI38, both cSrc and MAPK in VA13 were strongly activated regardless of FGF stimulation or GM3 depletion by P4. Continuous, constitutive activation of both cSrc and MAPK was due to (i) a much higher level of cSrc and FGFR in VA13 than in WI38 GEM, (ii) their close association/interaction in VA13 GEM as indicated by clear coimmunoprecipitation between cSrc and FGFR, and (iii) the absence of Csk in VA13 GEM, making GEM incapable of inhibiting cSrc activation.
authors.affiliation: Pacific Northwest Research Institute, 720 Broadway, Seattle, WA 98122-4302 , USA.
authors.forename: Marcos S
authors.initials: MS
authors.lastname: Toledo
authors.forename: Erika
authors.initials: E
authors.lastname: Suzuki
authors.forename: Kazuko
authors.initials: K
authors.lastname: Handa
authors.forename: Senitiroh
authors.initials: S
authors.lastname: Hakomori
mesh_terms: D015703:Antigens, CD / Q000096:biosynthesis / Q000378:metabolism; D002455:Cell Division; D002460:Cell Line; D002461:Cell Line, Transformed; D003505:Cyclodextrins / Q000378:metabolism; D005346:Fibroblast Growth Factors / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism*; D005679:G(M3) Ganglioside / Q000378:metabolism*; D006801:Humans; D008168:Lung / Q000378:metabolism*; D020935:MAP Kinase Signaling System; D008562:Membrane Glycoproteins / Q000378:metabolism; D018613:Microscopy, Confocal; D008856:Microscopy, Fluorescence; D008954:Models, Biological; D011137:Polystyrenes / Q000737:chemistry; D011233:Precipitin Tests; D017434:Protein Structure, Tertiary; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism; D012503:Saponins / Q000378:metabolism; D060225:Tetraspanin 28; D060245:Tetraspanin 29; D013997:Time Factors; D047392:beta-Cyclodextrins; D019061:src-Family Kinases / Q000378:metabolism
chemical_list: D015703:Antigens, CD; C554798:CD81 protein, human; C554869:CD9 protein, human; D003505:Cyclodextrins; D005679:G(M3) Ganglioside; D008562:Membrane Glycoproteins; D011137:Polystyrenes; D017468:Receptors, Fibroblast Growth Factor; D012503:Saponins; D060225:Tetraspanin 28; D060245:Tetraspanin 29; D047392:beta-Cyclodextrins; D005346:Fibroblast Growth Factors; D019061:src-Family Kinases; C031215:betadex